ROCKVILLE, Md., July 24,
2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced three presentations at the American Society of
Retina Specialists (ASRS) Annual Scientific Meeting, taking place
in Seattle, Washington from
July 28 through August 1, 2023. The
presentations will highlight data for ABBV-RGX-314, an
investigational one-time AAV therapeutic being developed in
collaboration with AbbVie for the treatment of wet AMD, DR and
other chronic retinal conditions, including new interim data from
the pharmacodynamic study of ABBV-RGX-314 delivered subretinally
using cGMP material produced by the company's
NAVXpress™ bioreactor platform process.
The presentations include:
Title: Subretinal Delivery of ABBV-RGX-314 for
Neovascular AMD: A Phase II Pharmacodynamic Study
Presenter: Ashkan M. Abbey, M.D., F.A.S.R.S., F.A.A.O.,
Director of Clinical Research at Texas Retina Associates –
Dallas and Clinical Assistant
Professor of Ophthalmology at UT Southwestern Medical Center
Session Title: Wet AMD Symposium 2
Date/Time: Sunday July 30,
8:00 am -8:06 am PDT
Type: Oral
Title: Suprachoroidal Delivery of ABBV-RGX-314 for
Neovascular AMD: Results from the Phase II AAVIATE Study
Presenter: David S. Boyer, M.D., Senior Partner,
Retina-Vitreous Associates Medical Group in Southern California
Session Title: Wet AMD Symposium 2
Date/Time: Sunday July 30,
8:06 am -8:10 am PDT
Type: Oral
Title: Suprachoroidal Delivery of ABBV-RGX-314 Gene
Therapy for Diabetic Retinopathy: The Phase II ALTITUDE Study
Presenter: Dilsher S. Dhoot, M.D.,Ophthalmologist at
California Retinal Consultants
Session Title: Diabetic Retinopathy 4
Date/Time: Tuesday August 1,
9:45 am – 9:51
am PDT
Type: Oral
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology
Platform Licensees are applying the NAV Technology Platform in the
development of a broad pipeline of candidates, including late-stage
and commercial programs, in multiple therapeutic areas. REGENXBIO
is committed to a "5x'25" strategy to progress five AAV
Therapeutics from its internal pipeline and licensed programs into
pivotal-stage or commercial products by 2025.
Contact:
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-upcoming-presentations-at-the-american-society-of-retina-specialists-annual-scientific-meeting-301884299.html
SOURCE REGENXBIO Inc.